More good news for patients with rare cholestatic liver diseases as the European regulatory advisory body, the Committee for Medicinal Products for Human Use (CHMP), gives Ipsen’s treatments for Primary Biliary Cholangitis and for Alagille Syndrome positive opinions. Following these recommendations for approval a final decision is expected from the European Commission later this year. #PrimaryBiliaryCholangitis #Alagillesyndrome
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Boulogne Billancourt
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
Nouvelles
-
We are celebrating the news that the European regulatory advisory body, the Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for two of our treatments for rare cholestatic liver disease on the same day. A final decision is expected from the European Commission later this year. Learn more: https://lnkd.in/dVtjUjMw
-
Ipsen announces partnership with Day One Biopharmaceuticals to bring tovorafenib to children living with pediatric low-grade glioma outside of the U.S.
-
🚀 Strong growth 📈 Progress in our portfolio 🌟 Exciting new assets in the pipeline The first half of the year has been a remarkable journey at Ipsen! We're incredibly proud of our employees' commitment to driving impactful results. Hear what CEO David Loew has to say.
-
Ipsen delivers strong results in the first half of 2024, upgrades its full-year guidance, progresses on launches and announces late-stage deal in oncology. Read more here: https://lnkd.in/efit2t5h
-
Ipsen announces partnership with Day One Biopharmaceuticals to bring tovorafenib to children living with pediatric low-grade glioma outside of the U.S. Learn more: https://lnkd.in/dkpWsizj
-
🌟 Brad’s Story 🌟 “You hear the first words, ‘You've got cancer’ and then you don't hear another word after that.” - Brad McKenzie. Brad shares his powerful journey with neuroendocrine cancer, from the shock of diagnosis to navigating life with the disease. Initially misdiagnosed, his story highlights the importance of listening to your body and seeking early detection. Brad emphasizes holistic health, both physical and mental, and the value of community support. His advice? "Connect with Neuroendocrine Cancer Australia for immediate support and resources." Don't miss Brad's inspiring story and his message of hope and resilience. 🔗Watch the full video here: https://lnkd.in/d_8QEHnX *In partnership with Ipsen, NeuroEndocrine Cancer Australia (NECA) presents the ‘Community Compass Campaign’, a disease awareness initiative empowering patients with neuroendocrine tumours (NETs) to navigate how they live with their condition through the shared experience of other people living with NETs.
-
We are thrilled to announce that HuntX Pharma has been awarded Ipsen’s Golden Ticket 2024, at BioLabs France cutting-edge Hôtel-Dieu de France facility. HuntX Pharma is pioneering a novel therapeutic approach for Huntington's disease, with promising potential applications for other neurological conditions. Congratulations to their exceptional team - we are delighted to support their journey.
-
🌍✨ Ipsen made a significant impact at the ESG Life Sciences Summit Europe 2024! 🌍✨ Gareth Collins, VP of Sustainability & EHS, presented our approach to CSRD compliance, emphasizing the integration of sustainability into our business transformation strategy, and showcased Generation Ipsen, our sustainability strategy. Learn more: https://lnkd.in/ecRkSXmN #ESG #Sustainability #LifeSciences #CSRD #GenerationIpsen
-
The right science at the right time. We are excited to explore the potential of Ipsen’s two ADCs, harnessing the power of novel targets and payloads to unlock their potential as we strive to bring new treatments to people living with hard to treat forms of cancer with few or no options. Read about Ipsen’s Early Development strategy here: https://lnkd.in/d-_y7zFi
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse29 134 597,00 $US